知搜-全球专利检索

  1. 登录
  2. 注册
发明授权
CN108245679B SPAG5作为靶位点在制备治疗膀胱癌药物中的应用 有权

SPAG5作为靶位点在制备治疗膀胱癌药物中的应用
摘要：
本发明研究表明，在原发性BUC组织中经常检测到SPAG5的上调，上调和下调SPAG5的表达分别增强或抑制体外和体内BUC细胞的增殖，并分别抑制或促进体外和体内细胞凋亡。因此，SPAG5作为靶位点在制备治疗膀胱癌药物中的应用，进一步的可以是制备治疗膀胱癌分子标志物，也可以是制备预测膀胱癌复发分子标记物中的应用。机制研究表明，SPAG5主要通过激活AKT/mTOR信号通路至少部分上调Wnt3促进BUC增殖并抑制BUC凋亡。因此，SPAG5可用于制备靶向负向调控Wnt3表达制剂。同时，Wnt3也作为靶位点在制备治疗膀胱癌药物中应用。
摘要（英）：

The invention discloses application of SPAG5 as a target site in preparing urinary bladder carcinoma treating medicine. Researches show that SPAG5 up-regulation can be frequently detected in primary BUC tissues, and increasing and reducing SPAG5 expression can respectively enhance or inhibit in-vitro and in-vivo BUC cell proliferation and can respectively inhibit or promote in-vitro and in-vivo cell apoptosis. Therefore, the SPAG5 can serve as the target site to be applied to preparing the urinary bladder carcinoma treating medicine and further can be applied to preparing urinary bladder carcinoma molecular markers and preparing urinary bladder carcinoma relapse predicting molecular markers. Mechanism researches show that the SPAG5 can promote BUC proliferation and inhibit BUC apoptosis mainly by activating AKT/mTOR signal channels and at least partially increasing Wnt3. Therefore, the SPAG5 can be applied to preparing target negative regulating Wnt3 expression preparation. Meanwhile,the Wnt3 also can serve as a target site to be applied to preparing urinary bladder carcinoma treating medicine.

公开/授权文献
0/0